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ABSTRACT 
OBJECTIVES: To analyze p53 mutations and gene expression of p53, ∆40p53 and ∆133p53 
isoforms in RCC tissues and normal adjacent tissue (NAT) and to associate them to clinical 
features and outcome.  
PATIENTS AND METHODS: Forty-one randomly selected patients, with primary, 
previously untreated RCC, with complete clinicopathohistological data were analyzed. NAT 
samples were available for 37 cases. Expression of p53, ∆40p53 and ∆133p53 was determined 
using RT-qPCR. A functional yeast-based assay was performed to analyze p53 mutations. 
RESULTS: More than half (56.1%) of patients harbored functional p53 mutations, and they 
were significantly younger than those with wild type (WT) p53 (P=0.032). Expression of p53, 
∆40p53 and ∆133p53 was upregulated in mutant (MT) p53 RCC compared to WT p53 RCC 
tissues. However, there was no difference in expression of these isoforms between MT p53 
RCC tissues and NAT. Expression of ∆133p53 was significantly downregulated in WT p53 
tissues compared to NAT (P=0.006). Patients that harbored functional p53 mutation had better 
overall survival (hazard ratio 4.32, 95% confidence interval 1.46-18.82, P=0.006). Multivariate 
analysis demonstrated that tumor stage and p53 mutation might be used as independent 
prognostic marker for overall survival in RCC patients. 
CONCLUSIONS: Our findings support the specific events in the carcinogenesis of RCC. p53 
isoforms can be differentially expressed depending on p53 mutational status.  
Keywords: p53, p53 isoforms, renal cell cancer, p53 mutation 
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1. INTRODUCTION 
Renal cell cancer (RCC) represents 2-3% of all cancers, with the highest incidence in Western 
countries [1,2]. Over the last two decades the incidence of RCC is increased, mostly due to 
increased detection of tumors by ultrasound and computed tomography [3]. The Tumor, Nodes, 
Metastasis (TNM) staging system is used to assess the anatomic extent of disease [4]. The most 
common histologic subtype is clear cell RCC which is believed to account for 80-90% of all 
RCCs [4]. Despite of all available prognostic markers, it seems that RCC follows an 
unpredictable disease course [5]. To improve the prognosis of the disease course, a better 
understanding of critical genes associated with disease progression is required. 
The p53 tumor suppressor protein is critical in the control of cell growth and the maintenance 
of genomic stability [6]. In contrast to other tumors, p53 is rarely mutated in RCCs suggesting 
that p53 function might be suppressed by other mechanisms [7-9]. p53 encodes 12 different 
isoforms that differ in their N- and C-terminus due to alternative splicing, promotor or 
translation initiation site [10]. The sum of their activities determines the p53-mediated cell 
response in a given tissue [6,11-13]. They have structural differences, different subcellular 
localization, they exert different effects on p53-mediated gene expression while some isoforms 
exhibit some functions independent of p53 [12,14-16]. The ∆40p53 isoform lacks the first 39 
amino acids and has lost the first transactivating domain but still retains the second one and the 
entire DNA binding domain. It has reduced ability to activate transcription of p53 mediated 
genes by itself, but it can form complexes with p53 and modulate p53-dependent gene 
expression in a positive and negative manner depending on its relative levels and cellular 
context [10,17]. ∆133p53 and ∆160p53 isoforms, produced from internal promoter P2, lack the 
first 132 and 159 amino acids, respectively and have lost both transactivating domains and a 
part of the first conserved cysteine box of the DNA binding domain. ∆133p53 forms 
heterocomplex with p53 and hence modulates gene expression in p53-independent way [13].  
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The expression of p53 isoforms has been shown to be dysregulated in several human cancer 
types, so we assume that in RCC p53 isoforms might participate in p53 inactivation, in tumor 
initiation and progression. The aim of this study was to analyze p53 mutation status in RCC 
tissues and mRNA expression of p53, ∆40p53 and ∆133p53 isoforms in RCC tissues and 
normal adjacent tissues (NAT), and to associate this information with clinical features and 
outcome.  
 
2. PATIENTS AND METHODS 
2.1. Patients’ data 
We prospectively analyzed 41 randomly selected patients with primary, previously untreated 
RCC, with complete clinicopathohistological data. Inclusion criteria were as followed: 1) 
histologically proven RCC (all cell types of RCC are eligible), 2) patients with all stages of 
disease according to TNM classification system, 3) patients were older than 18 years, 4) 
obtained written informed consent for the storage and use of their tissue and clinical information 
in this study. Thirty-seven patients underwent radical (90.2 %), and four patients partial 
nephrectomy (9.8%) at the University Hospital Centre Zagreb, Croatia, from November 2010 
until October 2013. Four patients (9.7%) had metastatic disease at the beginning of the study 
and thirteen patients (31.7%) had locally advanced RCC defined by TNM classification (T3/T4, 
N0, M0). This study complied with the Helsinki Declaration and was approved by the ethical 
committee from the University Hospital Centre Zagreb, Zagreb. Tissue samples were collected 
immediately after nephrectomy and evaluated by a pathologist; areas of histologically normal 
adjacent renal cell tissue were available for 37 cases. All clinical information was collected 
prospectively from hospital information system and anonymized. 
2.2. RNA extraction and RT-qPCR 
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Total RNA was extracted from 50-100 mg of tissue using TRIzol reagent (Thermo Fisher 
Scientific, USA) and subsequent RNA clean-up through RNeasy Mini Kit (Qiagen, USA) 
including DNase I treatment according to the manufacturer’s instructions. Total RNA was 
quantified and purity assessed using the BioSpec-nano Micro-volume UV-Vis 
Spectrophotometer (Shimadzu, Japan). RNA was reversely transcribed using High Capacity 
cDNA Reverse Transcription Kit (Thermo Fisher Scientific, USA) according to the 
manufacturer’s instructions. 
Absolute copy numbers were determined using the standard curve method by qPCR using the 
ABI Prism 7300 Detection System (Thermo Fisher Scientific). Reactions were performed in a 
final volume of 25 µl using the TaqMan® Universal PCR Master Mix (Thermo Fisher 
Scientific) under standard thermal cycling conditions (50°C for 2 min and 95°C for 10 min 
followed by 50 cycles at 95°C for 15 s and 60°C for 1 min). Primers and probes sequences 
(Metabion, Germany) are given in Supplementary Table S1. The absolute copies numbers were 
calculated from standard curves generated from serial dilutions of linearized plasmid construct 
carrying the amplicon with known concentration to allow copy numbers determination, and 
normalized to the average levels of housekeeping gene TATA box-binding protein (TBP). 
Reactions were conducted in duplicates. 
2.3. Functional Analysis of Separate Allele in Yeast (FASAY) 
We have adapted, and ad hoc modified the well-established FASAY assay [18], also known as 
Gap Repair Assay [18], in order to screen 41 patients for TP53 status. Briefly, cDNA obtained 
from RCC patients was used as template for a two-step PCR approach to amplify the TP53 
gene. The first-step PCR was performed using 25 µg of cDNA, the Go-Taq G2 Green Master 
Mix (Promega, USA), p53-Ex2.1-Fw (GTCACTGCCATGGAGGAGCCGCA) and p53-P4 
(ACCCTTTTTGGACTTCAGGTGGCTGGAGTG) primers (Eurofins Genomics, Germany). 
PCR products were diluted 1:400, and used for the second-step nested PCR using again Go-
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Taq G2 Green Master Mix but p53-P3 (ATTTGATGCTGTCCCCGGACGATATTGAAC) and 
p53-Ex10-Rv (CTTCCCAGCCTGGGCATCCTTG) more internal primers. cDNAs from 
MCF7 (WT p53) and MDA-MB-231 (only expressing the R280K p53 mutant allele) cells were 
used as negative and positive controls, respectively.  
Five or 10 µl of the second-step nested PCR product was added to 1.5 µl of double digested 
pRDI22 yeast expression plasmid (CEN/ARS, LEU2) and co-transformed in yeast using the 
Lithium acetate method [20] in the yeast reporter strain yIG397 that contains the ADE2 reporter 
gene under the control of a p53 Responsive Element. LEU2+ yeast colonies were selected on 
synthetic plates lacking leucine and containing limiting amount of adenine (5 mg/L). 
Transformant colonies were white in case of expression of WT p53, whereas MT p53 colonies 
appeared red. Colonies were counted, and red colony frequency (RCF) was calculated. Given 
the overall higher amount of background red colonies due to the two-step PCR approach (about 
15-20%), samples with an RCF higher than 60% were considered heterozygous for TP53. 
Samples with an RCF below 40% were scored as homozygous wild-type, while samples with 
almost all red colonies (RCF = 90-100%) were considered homozygous/hemizygous TP53 
mutants. Lastly, samples with an RCF score between 40 and 60% were uncertain and were re-
analyzed for a more accurate screening. However, heterozygous samples were considered 
mutant due to the fact that heterozygous state is often transient and the inactivation of the wild-
type allele is likely to happen. Moreover, many MT p53 proteins gain oncogenic activity which 
overcome the tumor suppressor activity of the remaining WT p53 allele[21]. 
2.4.Statistical analysis 
Normality of data was tested using D’Agostino and Pearson Omnibus test. Continuous variables 
were log transformed prior to analyses to distribute the data normally. ANOVA and Student’s 
t-test were used to determine the difference of p53 isoforms mRNA expression between various 
subgroups. Spearman’s correlation coefficient was used to calculate the correlation among p53 
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isoforms' expression. Isoforms' expression was dichotomized into "low" and "high" by a median 
value. The relationship between p53 isoforms' expression and p53 mutation status to clinical 
parameters was interrogated using chi-square test. Overall survival (OS) was determined with 
Kaplan-Meier method and log-rank test, while Cox proportional-hazards regression model was 
used for multivariate analysis. Statistical analyses were performed using MedCalc for 
Windows, version 17.6 (MedCalc Software, Belgium). Two-tailed P<0.05 was considered to 
be significant. 
 
3. RESULTS 
3.1. p53 mutation status in RCC patients 
For the analysis of p53 mutation status we used the FASAY that can distinguish inactivating 
mutations from functionally silent mutations. Table 1 summarizes the clinicopathological 
features of the cohort, as well as the results of p53 mutation analysis. More than half of the 
patients (56.1 %) harbored non-functional p53 mutations (including both homozygous (36.6%) 
and heterozygous (19.5%) mutants). Of note, p53 mutant cancers were associated with younger 
age at diagnosis (median 60 for MT p53 vs 69 years for WT p53, P=0.032). 
3.2. Low expression of p53 isoforms in RCC  
To determine gene expression of p53 isoforms in RCC, the mRNA expression of p53, Δ40p53 
and Δ133p53 was analyzed by RT-qPCR in 41 tumors and 37 matched NATs.  As shown in 
Supplement Table 2, Δ40p53 and Δ133p53 had remarkably weak expression compared to p53 
- the p53 median expression was 8.85 times higher than the median expression of Δ40p53 and 
16.32 times higher than the median expression of Δ133p53 isoform. Also, we observed 
significantly lower Δ133p53 expression in RCC tissues compared to NATs (P=0.002) (Figure 
1). In addition, the expression of each isoform within NATs and cancer tissues regardless of 
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p53 mutation status was highly associated with one another (Spearman’s rank correlation 
coefficients ranged from 0.700 to 0.886, all P values < 0.05). 
3.3.The expression of p53 isoforms in RCC is associated with p53 mutational status 
We have further analyzed whether the expression of p53 isoforms is associated with p53 
mutation status in RCC tissues (Supplementary Table S2). Cancer tissues that harbored p53 
mutations had a significantly higher expression of p53, Δ40p53 and particularly Δ133p53 
isoforms (P=0.0009, P=0.004 and P=0.0008, respectively) compared to WT p53 tumors (Figure 
2A.). When compared with NATs separately in WT p53 and MT p53 RCCs, only in WT p53 
cancer tissues Δ133p53 expression was significantly lower (P=0.006) (Figure 2B). We detected 
no significant alteration of isoform expression in MT p53 tumors compared to NATs (Figure 
2C).  
3.4.The association between p53 isoforms expression and clinical features 
Table 2 summarizes the association between p53 isoforms’ expression and clinical features. 
There was no significant difference in the expression of either p53, ∆40p53 or ∆133p53 in 
relation to gender, presence of symptoms, Fuhrman grade, histologic type, lymph node 
metastases, distant metastases and tumor stage according to TNM classification system. 
However, higher mRNA expression of p53 and ∆40p53 was associated with larger tumor size 
(P=0.044 and P=0.021, respectively) and more often renal capsular invasion (P=0.040 and 
P=0.013, respectively). Younger patients had higher expression of ∆133p53 isoform (P=0.032). 
3.5.The association of p53 isoforms expression and p53 mutational status with OS  
Next, we have investigated the connection between p53 isoform expression and OS. Median 
follow-up was 45 months (range 2 to 72 months). The median values for p53, Δ40p53 and 
Δ133p53 were used to fractionate samples into two groups, a high-expressing group, and a low-
expressing group. There was no difference in OS regarding the level of p53, Δ40p53 and 
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Δ133p53 expression (Figure 3A-C). However, we observed difference in OS of patients 
harboring WT p53 compared to those with p53 mutations (hazard ratio 4.32, 95% confidence 
interval (CI) 1.46-18.82, P=0.006) (Figure 3D). A median OS of 27 months (95% CI: 13.0- 
56.8 months) was observed in patients with WT p53 while it was 53 months (95% CI: 37.4-60 
months) in patients with MT p53. In the univariate analysis, Fuhrman grade, tumor stage, tumor 
size and p53 mutation status were statistically significant prognostic markers for OS (Table 3). 
In the multivariate model, only tumor stage and p53 mutation status can be considered as 
independent prognostic marker (Table 3). 
 
4. DISCUSSION 
The p53 regulates different cellular responses to stress including DNA repair, cell cycle arrest, 
proliferation, senescence, differentiation, cell migration and cell death, hence maintaining cell 
integrity. Therefore, p53 mutations, the most common genetic changes in human cancers, often 
are associated with worse disease outcome. Of note, p53 isoforms have distinct and independent 
roles in cancer. Several clinical studies have reported that p53 isoforms are abnormally 
expressed in human cancers suggesting that they could contribute to cancer formation and 
progression [22,23]. Two independent studies have determined the expression of p53 isoforms 
in RCC tissues so far, using semi-quantitative analysis of p53 isoforms levels. However, in both 
studies, p53 isoforms’ expression has not been associated with clinical features and outcome 
[24,25]. Also, many studies have analyzed p53 mutation status using immunostaining and 
sequencing methods, but none of them examined the functional mutation status of p53 in RCC 
tissues [26,27]. The aim of this study was to determine the expression of p53, ∆40p53 and 
∆133p53 isoforms in RCC and NATs, to determine the frequency of functional p53 mutations, 
and to associate the differential expression of isoforms and p53 mutational status with clinical 
features and outcome.  
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To this aim, we have determined the p53 status in our tumor collection using FASAY and 56.1% 
of tumors were identified as bearing a mutant p53 protein (either one or both alleles were 
mutated). The possible explanation for such a high frequency is the fact that most of the other 
studies have used immunochemical methods to detect p53 mutations [26,27]. In these studies, 
high-level expression of p53 is used as a surrogate mutation indicator due to abnormally 
extended half-live of mutant p53. However, in 10% to 20% of mutant p53 cases, tumors may 
harbor nonsense (truncating) mutations, which can lead to unstable mutant proteins, that will 
be expressed at low levels and falsely considered as WT p53 [9]. Furthermore, the majority of 
studies analyzed the central core domain of the gene (exons 4-8 or 5-8), the most common site 
of p53 mutations. However, approximately 15% of p53 mutations occur outside exons 5 
through 8, that is in exons 4, 9, and 10, and therefore, it is likely that there will be some 
underestimation of p53 mutations in these studies [9].  
The results of our study provide information about mRNA expression of p53 and N-truncated 
isoforms in RCC and NATs by RT-qPCR. Full-length p53 was the most expressed isoform in 
RCC tissues, while Δ40p53 and Δ133p53 were notably less expressed. This finding is consistent 
with study of Marabese and co-workers who had found low levels of Δ40p53 and Δ133p53 
isoforms in ovarian carcinoma compared to p53 expression [28]. Also, in squamous cell 
carcinoma of the head and neck, Δ133p53 expression is lower compared to transactivating full-
length isoforms of p53 (including p53β) [29]. 
We didn’t observe any significant difference in p53 and Δ40p53 expression in cancer tissues 
compared to NATs, while Δ133p53 isoform was downregulated in cancer tissues. The lack of 
overexpression of p53 in RCC could be explained on the basis of the study conducted with 
transgenic mice exposed to ionizing radiation, which have revealed that p53 is not necessarily 
upregulated in kidney tissues in response to stress and is less effective in kidney than in other 
tissues [30]. Moreover, it is well accepted that full-length p53 expression is generally not 
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modulated at the mRNA level, but rather at protein levels, often due to an array of several post-
translational modifications. In contrast to this observation, another RCC study detected 
upregulation of TAp53 isoforms (p53, p53β and p53ɣ), but no significant alteration of Δ133p53 
expression was detected in different tumor stages as compared to normal renal tissue [24]. 
However, downregulation of Δ133p53β and ɣ was found only in early tumor phases [24]. In 
another RCC study, Song and collaborators observed the significant upregulation of p53β 
isoform in tumor samples which correlated with tumor stage. Again, the other isoforms were 
expressed at different levels in both tumor and normal tissue but without statistical significance 
[25]. Both studies used semi-quantitative analysis of p53 isoforms expression and did not 
analyses p53 mutation status. 
We have associated the expression of p53 isoforms with p53 mutation status and found that the 
expression of all examined isoforms was higher in tumor tissues harboring mutant p53. In RCC 
tissues with WT p53 we have observed downregulation of ∆133p53 isoform when compared to 
NATs. In tumors harboring MT p53 down-regulation of ∆133p53 was not observed.  
As mentioned before, p53 and ∆40p53 are transcribed from P1 promoter, while ∆133p53 
expression is driven by alternative promoter P2 [22], which can be activated by p53 and 
suppressed by ∆40p53 through suppression of p53 functions [31]. It seems that in the cases that 
retained WT p53, the feedback regulatory loop might be altered, resulting in lower p53 activity 
on P2 promoter and downregulation of ∆133p53 isoforms. Based on these results, we speculate 
that dysregulation of p53 isoforms could contribute to cancer formation in WT p53 tissues. In 
addition, there was a trend of higher OS in patients with higher expression levels of p53 and 
∆133p53 isoforms (Figure 3A-C). Analysis of larger sample size might validate p53 isoform 
expression level as a prognostic biomarker in RCC patients.  
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One of the clinically most interesting findings in this study is the association of p53 mutant 
status with OS. Patients that harbored p53 mutation tumors had longer OS compared with 
patients with WT p53 tumors. This finding could be explained by the fact that patients with MT 
p53 tumors were significantly younger and might have less aggressive tumors (lower tumor 
stage) than those with WT p53 tumors since higher Fuhrman grade and tumor stage also have 
negative impact on OS (Figure 3D, Table 3). Also, they had higher levels of p53, ∆40p53 and 
∆133p53 isoform expression in RCC tissues and no difference in expression of isoforms in 
RCCs compared to NATs, suggesting that patients that have lower and dysregulated expression 
of p53 isoforms could have unfavorable clinical outcome even though they retained WT p53.  
These observations confirm the result of a previous study showing that silent p53 mutations or 
mutations in noncoding regions are associated with cancer formation probably because they 
lead to unbalanced p53 isoforms expression despite expressing WT p53 [12]. Altogether, our 
results suggest that the prognostic value of isoforms depend on p53 mutation status and the 
cancer type.  
The results of our research reveal specific combinations of isoforms expression and p53 
mutation status providing additional support for specific events in kidney carcinogenesis. These 
findings suggest that p53 function can be lost either by specific p53 isoforms’ expression or by 
mutations.  
Our study has limitations; we analyzed RNA expression rather than protein levels on a modest 
number of samples. At present, RT-qPCR represents the best method to specifically detect p53 
isoforms expression due to the lack of available isoform-specific antibodies. Using RT-qPCR 
we have focused to distinguish the expression level of N-terminal variants. However, we 
weren’t able to differentiate specifically all p53 isoforms due to excessively long amplicons for 
RT-qPCR and complex gene organization.  
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5. CONCLUSIONS 
This study provides critical information on the mRNA expression level of N-terminal isoforms 
in RCC in relation to p53 functional mutation status. Tumors with WT p53 had lower expression 
of p53, ∆40p53 and ∆133p53 isoforms comparing to MT p53 harboring tumors, and down-
regulation of ∆133p53 isoforms comparing to NAT. Our results underline the importance of 
considering both p53 mutational status and p53 isoforms’ expression in RCC clinical studies. 
Further studies are needed to determine the role of p53 isoform network in RCC carcinogenesis. 
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Abbreviation Term 
RCC renal cell cancer 
NAT normal adjacent tissue 
WT p53  wild-type p53 
MT p53 mutant p53 
OS overall survival 
RT-qPCR reverse transcription quantitative polymerase chain reaction 
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FIGURE LEGENDS    
Figure 1. Expression of p53, Δ40p53 and Δ133p53 isoforms in RCC tissues and NAT samples. Absolute 
quantification of p53, Δ40p53 and Δ133p53 by RT–qPCR in 41 tumors and 37 NATs. Results are shown 
as absolute copy numbers, expressed per standard input total RNA normalized to the average levels of 
housekeeping gene TATA box-binding protein (TBP). Values represent the median and interquartile 
range. Significant P values are shown in bold. 
Figure 2. Expression of p53, Δ40p53 and Δ133p53 isoforms in renal cell cancer tissues in association 
with p53 mutational status. Absolute quantification of p53, Δ40p53 and Δ133p53 isoforms by RT-qPCR 
in (A) 41 RCC tissues and (B,C) 37 matched RCC tissues and NAT in (B) wild type p53 tumors and (C) 
mutant p53 tumors. Results are shown as absolute copy numbers, expressed per standard input total 
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RNA normalized to the average levels of housekeeping gene TBP. T-test was used for testing difference 
between two groups. Values represent median and interquartile range. Significant P values are shown 
in bold. 
Figure 3. Kaplan-Meier plots depicting the impact of p53 isoforms’ expression and p53 mutational 
status on OS of patients with renal cell cancer. High (full line) or low (dotted line) expression of p53 
(A), Δ40p53 (B) and Δ133p53 (C) in 41 cases. Analysis of cases with MT (dotted line) or WT (full line) 
in 41 cases (D). The log rank (Mantel-Cox) test P values are shown. Tick marks indicate censored cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
